Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
March 05, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
March 01, 2018 16:52 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Added to NASDAQ Biotechnology Index
December 14, 2017 07:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 07, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
November 13, 2017 06:30 ET
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial...
Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
November 09, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
November 08, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
November 07, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
October 23, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...